10,020
+0.80%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GC Cell
Its shares trade on KOSDAQ under the ticker 144510.KQ. It has been listed since 23 June 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩165.52bn and a net loss of ₩272.86bn. At that date it held total assets of ₩303.69bn and shareholders' equity of ₩186.39bn.
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jun 2016
- Website
- gccell.com ↗
Leadership
Pay as last reported
- Mr. Seong Yong WonChief Executive Officer, Director, since 2023
- Mr. Ho Won KimChief Technology Officer, Managing Director, since 2023
- Mr. Chang Hwi LeeChief Administrative Officer, Assistant Managing Director
- Mr. Sun Yeong ParkChief Scientific Officer, Managing Director
- Mr. Jun Hui HanManaging Director, since 2021
- Mr. Gi Won KangManaging Director
- Ms. Ji Won JeonAssistant Managing Director, since 2023
- Ms. Seong Yun BahngAssistant Managing Director
- Mr. Seong Cheol ChoiInternal Auditor
- Mr. Yun ChoiAssistant Managing Director
- Mr. Chang Tae KimInternal Auditor
- Ms. Bo Gyeong MinAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GC Cell Corp. provides cell therapy services in the Health Care sector with strong biotechnology focus.
- GC Cell Corp. operates four business segments including cord blood storage and specimen testing.
- GC Cell Corp. has a strong presence in the Korean biotechnology market with its headquarters in Yongin.
Weaknesses
- GC Cell Corp. relies on a single market, South Korea, for its operations and revenue.
- GC Cell Corp. has limited international expansion beyond its domestic market.
- GC Cell Corp. depends on the biotechnology sector which faces regulatory challenges.
Opportunities
- GC Cell Corp. can expand its cord blood storage services to new markets in Asia.
- GC Cell Corp. can leverage its cell therapy segment for international clinical trials.
- GC Cell Corp. can grow its bio-logistics business in the Health Care industry.
Threats
- GC Cell Corp. faces competition from established biotechnology firms in South Korea.
- GC Cell Corp. is vulnerable to regulatory changes in the Health Care sector.
- GC Cell Corp. must navigate potential supply chain disruptions in the biotechnology industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.